Home Newsfeeds FDA Grants Approval Of Tzield To Provention Bio

FDA Grants Approval Of Tzield To Provention Bio

https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-can-delay-onset-type-1-diabetes

byBill Haddad

November 17, 2022

1 minute read

https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-can-delay-onset-type-1-diabetes

Trump SPAC Deal Nears End Days: Will Sept. 5 Mark Its Demise?

By Chris Katje

August 21, 2:22 PM

A SPAC merger to bring Donald Trump’s media company public was announced back in October 2021, and the deal for the TRUTH Social platform has yet to close.

DWAC

News

HWH International Provides Business Status Update; Says Confidence In Our Business, Laying A Robust Foundation As We Navigate Towards A Prosperous Year In 2024

By Benzinga Newsdesk

January 24, 10:11 AM

HWH International Inc. (NASDAQ:HWH) ("HWH") is pleased to offer an update on HWH's business operations since the successful completion of the business combination on January 9, 2024. As a public company listed on Nasdaq,

HWH

EMagin Drops After Earnings Miss: CEO Blames Mixed Results On Timing, Delayed Revenue

By Shivani Kumaresan

May 11, 11:06 AM

Electronics components maker eMagin Corp (NYSE: EMAN) reported first-quarter FY23 sales decline of 11% year-on-year to $6.59 million, missing the analyst consensus estimate of $7.56 mil

EMAN

Swiss And French Health Authorities Expand Recommendations For Use Of Nuvaxovid Covid-19 Vaccine As A Booster

By Benzinga Newsdesk

December 12, 9:58 AM

Dec 12, 2022 Novavax today announced that Switzerland’s Federal Office of Public Health (FOPH) and France’s Haute Autorité de Santé (HAS) have expanded their recommendations for use of

NVAX

FDA Grants Approval Of Tzield To Provention Bio

Related Posts

Trump SPAC Deal Nears End Days: Will Sept. 5 Mark Its Demise?

HWH International Provides Business Status Update; Says Confidence In Our Business, Laying A Robust Foundation As We Navigate Towards A Prosperous Year In 2024

EMagin Drops After Earnings Miss: CEO Blames Mixed Results On Timing, Delayed Revenue

Swiss And French Health Authorities Expand Recommendations For Use Of Nuvaxovid Covid-19 Vaccine As A Booster